A Randomized Trial of Telaprevir, Peginterferon, and Ribavirin Versus Peginterferon and Ribavirin for Treatment of Genotype 1 Hepatitis C Virus With Host Interleukin 28B CC Polymorphism.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 11 May 2017
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 24 Oct 2016 Status changed from discontinued to withdrawn prior to enrolment.
- 17 Sep 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Aug 2011 New trial record